INTRODUCTION: Platinum-based chemotherapy followed by the immune checkpoint inhibitor avelumab represents an intensified upfront therapy regimen that may result in significant downstaging and, subsequently, potentially radical robotic nephroureterectomy with a lymph node dissection, an uncommon approach with an unexpectedly favorable outcome. CASE PRESENTATION: We report a case of a 70-year-old female presented with a sizeable cN2+ tumor of the left renal pelvis and achieved deep partial radiologic response after systemic therapy with four cycles of gemcitabine-cisplatin chemotherapy followed by avelumab maintenance therapy and subsequent robotic resection of the tumor. The patient continued with adjuvant nivolumab therapy once recovered after surgery and remained tumor-free on the subsequent follow-up. The systemic treatment was without any severe adverse reaction. CONCLUSION: We highlight the feasibility of the upfront systemic therapy with four cycles of gemcitabine-cisplatin chemotherapy followed by avelumab maintenance, robotic-assisted removal of the tumor, and adjuvant immunotherapy with nivolumab. This intensification of the upfront systemic therapy, and the actual treatment sequence significantly increase the chances of prolonged survival or even a cure. This type of personalized therapeutic approach can accelerate future advanced immunotherapeutic strategies.

Department of Clinical and Molecular Pathology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Department of Oncology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Department of Urology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Czechia

Zobrazit více v PubMed

Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. . Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur Urol. (2012) 62:100–14. doi: 10.1016/j.eururo.2012.02.030 PubMed DOI

Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, et al. . Rates of Other-Cause Mortality after Radical Cystectomy Are Decreasing over Time-a Population-Based Analysis over Two Decades. J Surg Oncol. (2020) 121:1329–36. doi: 10.1002/jso.v121.8 PubMed DOI

Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, et al. . Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the pout trial. J Clin Oncol. (2024) 42:1466–71. doi: 10.1200/JCO.23.01659 PubMed DOI PMC

Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. . Adjuvant chemotherapy in upper tract urothelial carcinoma (the pout trial): A phase 3, open-label, randomised controlled trial. Lancet. (2020) 395:1268–77. doi: 10.1016/S0140-6736(20)30415-3 PubMed DOI PMC

Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, et al. . Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis. Oncologist. (2016) 21:708–15. doi: 10.1634/theoncologist.2015-0440 PubMed DOI PMC

Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, et al. . Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. (2010) 116:3127–34. doi: 10.1002/cncr.v116:13 PubMed DOI

Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, et al. . Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol. (2018) 200:68–73. doi: 10.1016/j.juro.2017.12.054 PubMed DOI

Almassi N, Gao T, Lee B, Stein RJ, Haber GP, Ornstein MC, et al. . Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery. Clin Genitourin Cancer. (2018) 16:e1237–42. doi: 10.1016/j.clgc.2018.08.003 PubMed DOI

Meng X, Chao B, Vijay V, Silver H, Margolin EJ, Balar A, et al. . High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma. Urology. (2019) 129:146–52. doi: 10.1016/j.urology.2019.01.058 PubMed DOI

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, et al. . Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. Cancer. (2019) 125:3155–63. doi: 10.1002/cncr.v125.18 PubMed DOI PMC

Martini A, Daza J, Poltiyelova E, Gul Z, Heard JR, Ferket BS, et al. . Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int. (2019) 124:665–71. doi: 10.1111/bju.v124.4 PubMed DOI

Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, et al. . European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. (2023) 84:49–64. doi: 10.1016/j.eururo.2023.03.013 PubMed DOI

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. . Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. New Engl J Med. (2020) 383:1218–30. doi: 10.1056/NEJMoa2002788 PubMed DOI

Shigeta K, Matsumoto K, Ogihara K, Murakami T, Anno T, Umeda K, et al. . Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol. (2022) 40:105.e19–105.e26. doi: 10.1016/j.urolonc.2021.07.029 PubMed DOI

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. . Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. (2021) 384:2102–14. doi: 10.1056/NEJMoa2034442 PubMed DOI PMC

Laukhtina E, Sari Motlagh R, Mori K, Katayama S, Rajwa P, Yanagisawa T, et al. . Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol. (2022) 169:103570. doi: 10.1016/j.critrevonc.2021.103570 PubMed DOI

Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, et al. . Phase ii trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol. (2020) 203:690–8. doi: 10.1097/JU.0000000000000644 PubMed DOI PMC

Coleman JA, Yip W, Wong NC, Sjoberg DD, Bochner BH, Dalbagni G, et al. . Multicenter phase ii clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma. J Clin Oncol. (2023) 41:1618–25. doi: 10.1200/JCO.22.00763 PubMed DOI PMC

Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. (2014) 66:529–41. doi: 10.1016/j.eururo.2014.03.003 PubMed DOI

Kim DK, Lee JY, Kim JW, Hah YS, Cho KS. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. (2019) 135:59–65. doi: 10.1016/j.critrevonc.2019.01.019 PubMed DOI

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: A 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. (2021) 79:635–54. doi: 10.1016/j.eururo.2020.07.003 PubMed DOI

Ali Deb A, Chitteti P, Naushad N, Asaad W, Leung S, Hartley A, et al. . Role of neoadjuvant chemotherapy on pathological, functional, and survival outcomes of upper tract urothelial carcinoma patients: A systematic review and meta-analysis. Urol Res Pract. (2024) 50:13–24. doi: 10.5152/tud.2024.23214 PubMed DOI PMC

Chen L, Ou Z, Wang R, Zhang M, He W, Zhang J, et al. . Neoadjuvant chemotherapy benefits survival in high-grade upper tract urothelial carcinoma: A propensity score-based analysis. Ann Surg Oncol. (2020) 27:1297–303. doi: 10.1245/s10434-019-08128-7 PubMed DOI

Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, et al. . Oncologic outcomes in patients with residual upper tract urothelial carcinoma following neoadjuvant chemotherapy. Eur Urol Oncol. (2024) 7:1061–8. doi: 10.1016/j.euo.2024.01.010 PubMed DOI

Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, et al. . The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: A multi-institutional study. Eur Urol. (2014) 65:227–34. doi: 10.1016/j.eururo.2012.11.050 PubMed DOI

Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. (2015) 41:310–9. doi: 10.1016/j.ctrv.2015.02.006 PubMed DOI

Bitaraf M, Ghafoori Yazdi M, Amini E. Upper tract urothelial carcinoma (Utuc) diagnosis and risk stratification: A comprehensive review. Cancers (Basel). (2023) 15:4987. doi: 10.3390/cancers15204987 PubMed DOI PMC

Liu J, Lai S, Wu P, Wang J, Wang J, Wang J, et al. . Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy. J Cancer Res Clin Oncol. (2023) 149:10893–909. doi: 10.1007/s00432-023-04977-8 PubMed DOI

Liu J, Wu P, Lai S, Song X, Wang M, Wang X, et al. . Clinicopathological and prognostic significance of preoperative prognostic nutritional index in patients with upper urinary tract urothelial carcinoma. Nutr Cancer. (2022) 74:2964–74. doi: 10.1080/01635581.2022.2049829 PubMed DOI

Mori K, Janisch F, Mostafaei H, Lysenko I, Kimura S, Egawa S, et al. . Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. Urol Oncol. (2020) 38:315–33. doi: 10.1016/j.urolonc.2020.01.015 PubMed DOI

Necchi A, Martini A, Raggi D, Cucchiara V, Colecchia M, Lucianò R, et al. . A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: pure-02. Urol Oncol. (2022) 40:10.e1–6. doi: 10.1016/j.urolonc.2021.05.014 PubMed DOI

Teo MY, Guercio BJ, Pietzak EJ, Ponomarev M, Regazzi AM, Quinlan C, et al. . Neoadjuvant nivolumab (N) + Ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (Utuc). J Clin Oncol. (2023) 41:51. doi: 10.1200/JCO.2023.41.6_suppl.511 DOI

Xu L, Wang D, Wu Y, Zhang C, Miao P. Immunotherapy combined with chemotherapy in neoadjuvant therapy for locally advanced renal pelvis carcinoma: A case report and literature review. IJS Oncol. (2022) 7:68–74. doi: 10.29337/ijsonco.141 DOI

Chan WN, Huang YC, Ho DR, Chen CS. Case report: neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis. Front Oncol. (2022) 12:985177. doi: 10.3389/fonc.2022.985177 PubMed DOI PMC

Ikarashi D, Kitano S, Ishida K, Nakatsura T, Shimodate H, Tsuyukubo T, et al. . Complete pathological response to neoadjuvant pembrolizumab in a patient with chemoresistant upper urinary tract urothelial carcinoma: A case report. Front Oncol. (2020) 10:564714. doi: 10.3389/fonc.2020.564714 PubMed DOI PMC

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, et al. . Prognostic value of pd-1 and pd-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol. (2017) 198:1253–62. doi: 10.1016/j.juro.2017.06.086 PubMed DOI

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. . Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated fgfr3 signaling. Nat Commun. (2019) 10:2977. doi: 10.1038/s41467-019-10873-y PubMed DOI PMC

Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, et al. . Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. (2020) 77:701–10. doi: 10.1016/j.eururo.2020.02.028 PubMed DOI

Kondo T, Hashimoto Y, Kobayashi H, Iizuka J, Nakazawa H, Ito F, et al. . Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol. (2010) 17:848–54. doi: 10.1111/j.1442-2042.2010.02610.x PubMed DOI

Saini S, Pathak RA, Hemal AK. Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care? Int Urol Nephrol. (2022) 54:1777–85. doi: 10.1007/s11255-022-03225-1 PubMed DOI

Simone G, Papalia R, Guaglianone S, Ferriero M, Leonardo C, Forastiere E, et al. . Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol. (2009) 56:520–6. doi: 10.1016/j.eururo.2009.06.013 PubMed DOI

Peyronnet B, Seisen T, Dominguez-Escrig JL, Bruins HM, Yuan CY, Lam T, et al. . Oncological outcomes of laparoscopic nephroureterectomy versus open radical nephroureterectomy for upper tract urothelial carcinoma: an european association of urology guidelines systematic review. Eur Urol Focus. (2019) 5:205–23. doi: 10.1016/j.euf.2017.10.003 PubMed DOI

Rodriguez JF, Packiam VT, Boysen WR, Johnson SC, Smith ZL, Smith ND, et al. . Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol. (2017) 31:661–5. doi: 10.1089/end.2017.0086 PubMed DOI

Clements MB, Krupski TL, Culp SH. Robotic-assisted surgery for upper tract urothelial carcinoma: A comparative survival analysis. Ann Surg Oncol. (2018) 25:2550–62. doi: 10.1245/s10434-018-6557-8 PubMed DOI

Veccia A, Antonelli A, Francavilla S, Simeone C, Guruli G, Zargar H, et al. . Robotic versus other nephroureterectomy techniques: A systematic review and meta-analysis of over 87,000 cases. World J Urol. (2020) 38:845–52. doi: 10.1007/s00345-019-03020-1 PubMed DOI

Tinay I, Gelpi-Hammerschmidt F, Leow JJ, Allard CB, Rodriguez D, Wang Y, et al. . Trends in utilisation, perioperative outcomes, and costs of nephroureterectomies in the management of upper tract urothelial carcinoma: A 10-year population-based analysis. BJU Int. (2016) 117:954–60. doi: 10.1111/bju.2016.117.issue-6 PubMed DOI

Liedberg F, Hagberg O, Aljabery F, Gårdmark T, Jahnson S, Jerlström T, et al. . Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: A population-based survey. Scand J Urol. (2024) 59:19–25. doi: 10.2340/sju.v59.16281 PubMed DOI

Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, et al. . Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol. (2018) 36:9.e1–9. doi: 10.1016/j.urolonc.2017.09.001 PubMed DOI

Kenigsberg AP, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, et al. . Robotic nephroureterectomy vs laparoscopic nephroureterectomy: increased utilization, rates of lymphadenectomy, decreased morbidity robotically. J Endourol. (2021) 35:312–8. doi: 10.1089/end.2020.0496 PubMed DOI

Reese SW, Eismann L, White C, Villada JA, Khaleel S, Ostrovnaya I, et al. . Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. Urol Oncol. (2024) 42:32.e9–32.e16. doi: 10.1016/j.urolonc.2023.12.003 PubMed DOI PMC

Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, et al. . Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. (2014) 120:1794–9. doi: 10.1002/cncr.v120.12 PubMed DOI PMC

Kobayashi K, Saito T, Kitamura Y, Bilim V, Toba T, Kawasaki T, et al. . Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. Int J Urol. (2016) 23:153–8. doi: 10.1111/iju.2016.23.issue-2 PubMed DOI

Kubota Y, Hatakeyama S, Tanaka T, Fujita N, Iwamura H, Mikami J, et al. . Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: A multicenter study. Oncotarget. (2017) 8:101500–8. doi: 10.18632/oncotarget.21551 PubMed DOI PMC

Hosogoe S, Hatakeyama S, Kusaka A, Hamano I, Iwamura H, Fujita N, et al. . Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus. (2018) 4:946–53. doi: 10.1016/j.euf.2017.03.013 PubMed DOI

Zennami K, Sumitomo M, Takahara K, Nukaya T, Takenaka M, Fukaya K, et al. . Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma. BJU Int. (2021) 127:332–9. doi: 10.1111/bju.v127.3 PubMed DOI PMC

Kohada Y, Hayashi T, Takemoto K, Miyamoto S, Babasaki T, Kobatake K, et al. . The efficacy of neoadjuvant gemcitabine and cisplatin chemotherapy for ct3n0m0 upper tract urothelial carcinoma: the impact of tumor location. Urol J. (2023) 21:98–106. doi: 10.22037/uj.v20i.7611 PubMed DOI

Ni K, Yu C, Wang H, Zhu S, Yu S, Li G. Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review. Heliyon. (2023) 9:e15813. doi: 10.1016/j.heliyon.2023.e15813 PubMed DOI PMC

Chan KH, Shu T, Al Shaarani M, Cen P. Complete pathologic response with pembrolizumab and enfortumab vedotin in urothelial carcinoma of the upper urinary tract. J Investig Med High Impact Case Rep. (2024) 12:23247096241257333. doi: 10.1177/23247096241257333 PubMed DOI PMC